218 related articles for article (PubMed ID: 17575540)
1. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
[TBL] [Abstract][Full Text] [Related]
2. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
Liao WC; Wu MS; Wang HP; Tien YW; Lin JT
Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136
[TBL] [Abstract][Full Text] [Related]
3. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lekstan A; Olakowski M; Jablonska B; Lewinski A; Musialski P; Sobczyk W; Kapalka A; Lampe P
J Physiol Pharmacol; 2015 Oct; 66(5):653-63. PubMed ID: 26579571
[TBL] [Abstract][Full Text] [Related]
4. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
5. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
7. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
8. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
[TBL] [Abstract][Full Text] [Related]
9. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.
Malaguarnera M; Cristaldi E; Cammalleri L; Colonna V; Lipari H; Capici A; Cavallaro A; Beretta M; Alessandria I; Luca S; Motta M
Arch Gerontol Geriatr; 2009; 48(2):213-7. PubMed ID: 18329114
[TBL] [Abstract][Full Text] [Related]
10. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms.
Pezzilli R; Barassi A; Corsi MM; Morselli-Labate AM; Campana D; Casadei R; Santini D; Corinaldesi R; D'Eril GM
Scand J Gastroenterol; 2010; 45(1):93-9. PubMed ID: 19883273
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
12. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
13. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
14. Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer.
Gasiorowska A; Talar-Wojnarowska R; Kaczka A; Borkowska A; Czupryniak L; Małecka-Panas E
Dig Dis Sci; 2016 Apr; 61(4):1121-9. PubMed ID: 26597191
[TBL] [Abstract][Full Text] [Related]
15. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
Markocka-Maczka K
Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
[TBL] [Abstract][Full Text] [Related]
16. Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis.
Birk D; Gansauge F; Gansauge S; Schwarz A; Beger HG
Eur J Med Res; 1999 Apr; 4(4):156-60. PubMed ID: 10205291
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer.
Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H
Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715
[TBL] [Abstract][Full Text] [Related]
18. Molecular angiogenesis profile as a tool to discriminate chronic pancreatitis (CP) from pancreatic cancer (PC).
Berindan-Neagoe I; Burz C; Balacescu O; Balacescu L; Seicean A; Cristea V; Irimie A
Pancreas; 2011 Apr; 40(3):482-3. PubMed ID: 21412121
[No Abstract] [Full Text] [Related]
19. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis.
Gold DV; Modrak DE; Ying Z; Cardillo TM; Sharkey RM; Goldenberg DM
J Clin Oncol; 2006 Jan; 24(2):252-8. PubMed ID: 16344318
[TBL] [Abstract][Full Text] [Related]
20. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
Santander C; Jiménez I; Martín E; Melón A; Pajares JM
Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
